Literature DB >> 16596223

Abnormal activation of the synuclein-gamma gene in hepatocellular carcinomas by epigenetic alteration.

Wei Zhao1, Haiyan Liu, Wei Liu, Yinwei Wu, Wei Chen, Bin Jiang, Yue Zhou, Rong Xue, Chan Luo, Lan Wang, Jian-Dong Jiang, Jingwen Liu.   

Abstract

Liver cancer is the fifth most common neoplastic disease and the fourth leading cause of cancer-related death. Identification of the key molecular targets involved in hepatocarcinogenesis has significant therapeutic implications. In this study, by conducting immunohistochemistry, we show that the neuronal protein, synuclein-gamma (SNCG), is abnormally expressed in a high percentage of liver cancer (46/70, 65.7%). The expression of SNCG in liver cancer exhibits a clear stage-specific pattern of low expression in stage I (1/19, 5.3%) and high expression in stages III to IV (44/50, 88%). Importantly, all patients with metastatic diseases expressed SNCG in their primary tumors (15/15, 100%). Consistent with the IHC results, RT-PCR assays demonstrate that SNCG mRNA is highly expressed in the tumor tissue of advanced hepatocellular carcinomas. Analyses of the methylation status of the CpG island of the SNCG gene by methylation-specific PCR confirmed that all tumor samples contained the demethylated gene. To determine whether demethylation of SNCG is an early event of genetic abnormality in the process of hepatocarcinogenesis, we examined the methylation status of SNCG in 70 non-malignant cirrhotic liver samples and showed that 64.3% cirrhotic liver samples contained the partially or completely demethylated gene. We further show that SNCG expression in liver cancer is not restricted to HBV- and HCV-infected tumors, implying the involvement of other hepatocarcinogenic risk factors in SNCG gene reactivation. Utilizing human hepatoma-derived cell line HepG2 as an in vitro model, we demonstrate that hepatic carcinogens aflatoxin B1 and N-nitrosodimethylamine (DMN) are strong inducers of SNCG expression. Collectively, these new findings suggest that SNCG protein expression in primary tumors is a strong indicator of distant metastasis and demethylation of SNCG CpG island is an early sign of genetic abnormality in liver cirrhosis preceding hepatocarcinogenesis. Our studies also suggest that inducing demethylation of SNCG by hepatocarcinogens may represent one underlying mechanism for the aberrant expression of SNCG in HCC.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16596223

Source DB:  PubMed          Journal:  Int J Oncol        ISSN: 1019-6439            Impact factor:   5.650


  18 in total

Review 1.  Role of epigenetic aberrations in the development and progression of human hepatocellular carcinoma.

Authors:  Igor P Pogribny; Ivan Rusyn
Journal:  Cancer Lett       Date:  2012-02-02       Impact factor: 8.679

2.  Expression of gamma-synuclein in colorectal cancer tissues and its role on colorectal cancer cell line HCT116.

Authors:  Qing Ye; Bo Feng; Yuan-Fei Peng; Xue-Hua Chen; Qu Cai; Bei-Qin Yu; Liang-Hui Li; Ming-Yuan Qiu; Bing-Ya Liu; Min-Hua Zheng
Journal:  World J Gastroenterol       Date:  2009-10-28       Impact factor: 5.742

3.  The reciprocal regulation of gamma-synuclein and IGF-I receptor expression creates a circuit that modulates IGF-I signaling.

Authors:  Minjing Li; Yancun Yin; Hui Hua; Xiangming Sun; Ting Luo; Jiao Wang; Yangfu Jiang
Journal:  J Biol Chem       Date:  2010-07-29       Impact factor: 5.157

Review 4.  DNA methylation of cancer genome.

Authors:  Hoi-Hung Cheung; Tin-Lap Lee; Owen M Rennert; Wai-Yee Chan
Journal:  Birth Defects Res C Embryo Today       Date:  2009-12

5.  Synuclein gamma predicts poor clinical outcome in colon cancer with normal levels of carcinoembryonic antigen.

Authors:  Caiyun Liu; Bin Dong; Aiping Lu; Like Qu; Xiaofang Xing; Lin Meng; Jian Wu; Y Eric Shi; Chengchao Shou
Journal:  BMC Cancer       Date:  2010-07-07       Impact factor: 4.430

6.  Synuclein gamma protects HER2 and renders resistance to Hsp90 disruption.

Authors:  Yongfeng Shao; Bingchan Wang; Dorothy Shi; Suyu Miao; Panneerselvam Manivel; Ramadas Krishna; Yiding Chen; Y Eric Shi
Journal:  Mol Oncol       Date:  2014-06-14       Impact factor: 6.603

7.  Changes in glucose metabolism and gene expression after transfer of anti-angiogenic genes in rat hepatoma.

Authors:  Uwe Haberkorn; Johannes Hoffend; Kerstin Schmidt; Annette Altmann; Gabriel A Bonaterra; Antonia Dimitrakopoulou-Strauss; Ludwig G Strauss; Michael Eisenhut; Ralf Kinscherf
Journal:  Eur J Nucl Med Mol Imaging       Date:  2007-08-15       Impact factor: 9.236

Review 8.  DNA hypomethylation in cancer cells.

Authors:  Melanie Ehrlich
Journal:  Epigenomics       Date:  2009-12       Impact factor: 4.778

Review 9.  Environmental toxicants, epigenetics, and cancer.

Authors:  Igor P Pogribny; Ivan Rusyn
Journal:  Adv Exp Med Biol       Date:  2013       Impact factor: 2.622

10.  Pharmacological inhibition of DNA methylation induces proinvasive and prometastatic genes in vitro and in vivo.

Authors:  Bushra Ateeq; Alexander Unterberger; Moshe Szyf; Shafaat A Rabbani
Journal:  Neoplasia       Date:  2008-03       Impact factor: 5.715

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.